2024
Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer.
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 10668969241256109. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with <i>TP53</i> mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53</i> mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival time
2023
The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.Peer-Reviewed Original ResearchConceptsMetastatic tumorsBreast carcinomaGenetic aberrationsPR statusPrimary tumorBreast cancerControl groupER/PR statusEstrogen receptor-positive breast carcinomasER-positive breast cancerER positivity rateMetastatic breast cancerProgesterone receptor statusMetastatic breast carcinomaMore liver metastasesPrimary breast carcinomaWild-type groupEstrogen receptor 1 geneReceptor 1 geneWild-type controlsLiver metastasesReceptor statusClinicopathological featuresER expressionControl tumors
2022
Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities
Gohar J, Do W, Miller-Kleinhenz J, Conneely K, Krishnamurti U, D’Angelo O, Gogineni K, Torres M, Gabram-Mendola S, McCullough L. Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities. Breast Cancer Research And Treatment 2022, 191: 653-663. PMID: 34978015, DOI: 10.1007/s10549-021-06430-1.Peer-Reviewed Original ResearchConceptsNeighborhood-level factorsCause mortalityMultivariable Cox proportional hazards modelsCox proportional hazards modelCancer outcome disparitiesBreast cancer outcomesTumor methylationProportional hazards modelNon-Hispanic blacksArea-level factorsCancer outcomesFalse discovery rate thresholdBody of evidenceCancer disparitiesBreast cancerOutcome disparitiesCpG sitesTumor progressionTumor tissueWhite womenGuanine dinucleotide sitesRacial disparitiesMortalityTumor epigenomeLinear regression models
2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
Zhao J, Krishnamurti U, Zhang C, Meisel J, Wei Z, Suo A, Aneja R, Li Z, Li X. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology - Research And Practice 2020, 216: 153155. PMID: 32871536, DOI: 10.1016/j.prp.2020.153155.Peer-Reviewed Original ResearchConceptsHigh HER2/CEP17 ratioHER2/CEP17 ratioTumor responseBreast cancer casesNeoadjuvant HER2CEP17 ratioNeoadjuvant chemotherapyIHC 3Breast cancerCancer casesRCB II/IIIHER2-positive breast cancerHER2 IHC 3Complete pathologic responseResidual cancer burdenSmaller tumor sizePositive breast cancerLow nuclear gradeHER2 copy numberHigh Ki67Pathologic responseCancer burdenExcisional specimensPositive cancersTumor sizeDetection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer
Maliniak M, Cheriyan A, Sherman M, Liu Y, Gogineni K, Liu J, He J, Krishnamurti U, Miller-Kleinhenz J, Ashiqueali R, He J, Yacoub R, McCullough L. Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer. Breast Cancer Research 2020, 22: 65. PMID: 32552729, PMCID: PMC7298873, DOI: 10.1186/s13058-020-01308-4.Peer-Reviewed Original ResearchConceptsBreast adipose tissueHazard ratioBreast cancerAdipose tissueMultivariable Cox proportional hazards modelsWhite womenCox proportional hazards modelProgression-free survivalMedical record reviewCurrent smoking statusConfidence intervalsProportional hazards modelBenign breast tissueBreast cancer prognosisNon-tumor tissuesCrown-like structuresMulti-racial populationEvidence of associationWorse OSWhite patientsClinical outcomesRecord reviewSmoking statusLifestyle factorsMultivariable modelObesity-associated methylation in breast tumors: a possible link to disparate outcomes?
Do W, Conneely K, Gabram-Mendola S, Krishnamurti U, D’Angelo O, Miller-Kleinhenz J, Gogineni K, Torres M, McCullough L. Obesity-associated methylation in breast tumors: a possible link to disparate outcomes? Breast Cancer Research And Treatment 2020, 181: 135-144. PMID: 32236829, DOI: 10.1007/s10549-020-05605-6.Peer-Reviewed Original ResearchConceptsCause mortalityER statusMultivariable Cox proportional hazards modelsCox proportional hazards modelBreast cancer tumor tissuesBreast cancer outcomesBreast cancer incidenceEstrogen receptor statusBody mass indexPrimary risk factorNon-Hispanic blacksCancer tumor tissuesReceptor statusMass indexCancer outcomesCpG sitesRisk factorsCancer incidenceBreast cancerHazards modelBreast tumorsTumor tissueWhite womenObesityRace disparities
2019
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer
Meisel J, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer 2019, 20: 19-24. PMID: 31806448, DOI: 10.1016/j.clbc.2019.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreastBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantDNA Copy Number VariationsDrug Resistance, NeoplasmFeasibility StudiesFemaleHumansLymphocytes, Tumor-InfiltratingMastectomyMiddle AgedNeoadjuvant TherapyPredictive Value of TestsProgression-Free SurvivalReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTumor BurdenConceptsTumor-infiltrating lymphocytesHER2-positive breast cancerNeoadjuvant therapyHER2/CEP17 ratioBreast cancerClinicopathologic featuresTumor sizeEstrogen receptorKi-67High HER2/CEP17 ratioCEP17 ratioHER2 immunohistochemistry 3Pathologic complete responseProgesterone receptor expressionSmaller tumor sizeBreast cancer responseHigh Ki-67Low estrogen receptorHER2 copy numberRCB-IIPatient ageClinicopathologic factorsComplete responseInitial biopsyExcisional specimensA whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk
Klimov S, Miligy I, Gertych A, Jiang Y, Toss M, Rida P, Ellis I, Green A, Krishnamurti U, Rakha E, Aneja R. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research 2019, 21: 83. PMID: 31358020, PMCID: PMC6664779, DOI: 10.1186/s13058-019-1165-5.Peer-Reviewed Original ResearchConceptsDCIS patientsRecurrence riskDuctal carcinomaScreen-detected breast cancerLong-term outcome dataBreast-conserving surgeryUnmet clinical needNottingham University HospitalsPositive predictive valueAdjuvant radiationIpsilateral recurrenceAdditional therapyMethodsThe cohortHazard ratioLocal recurrenceClinicopathological markersClinicopathological variablesPrimary tumorUniversity HospitalLymphocyte regionBreast cancerOutcome dataBenign ductsPredictive valuePatientsPrognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li X, Oprea-Ilies G, Wetherilt C, Riaz A, Aleskandarany M, Green A, Ellis I, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen E, Callagy G, Walsh E, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada H, Omonisi A, Ahmed S, Rakha E, Rida P, Aneja R. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers 2019, 11: 995. PMID: 31319547, PMCID: PMC6678933, DOI: 10.3390/cancers11070995.Peer-Reviewed Original ResearchTriple-negative breast cancerAR-positive triple-negative breast cancerAndrogen receptorAR statusPrognostic roleOverall survivalBetter prognosisBreast cancerAR-positive nucleiPatients' overall survivalReliable prognostic markersNegative breast cancerPotential therapeutic targetMulti-institutional studyAR positivityTNBC patientsPoor prognosisPrognostic valuePrimary tumorPatient prognosisIndian cohortPrognostic markerUK cohortAR antibodyTNBC samples
2017
GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma
Bivin W, Yergiyev O, Bunker M, Silverman J, Krishnamurti U. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2017, 25: 553-558. PMID: 26945445, DOI: 10.1097/pai.0000000000000349.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaHER2 amplificationHER2 overexpressionER negativityPathologic stageHistologic gradeP53 positivityGRB7 expressionBreast cancerBreast carcinomaInvasive breast cancer correlatesInvasive breast cancerBreast cancer correlatesChromosome 17 copy numberAntiestrogen therapyPR expressionPredictive factorsHER2 expressionCancer correlatesPR testingP53 immunohistochemistryAggressive phenotypeHER2 geneHER2P53 statusHER3-EGFR score to predict clinical outcomes in triple-negative breast cancer.
Ogden A, Bhattarai S, Green A, Aleskandarany M, Rakha E, Ellis I, Li X, Krishnamurti U, Janssen E, Jonsdottir K, Reid M, Rida P, Aneja R. HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer. Journal Of Clinical Oncology 2017, 35: 11612-11612. DOI: 10.1200/jco.2017.35.15_suppl.11612.Peer-Reviewed Original ResearchTNBC patientsDistant metastasisPrognostic valueBreast cancerCox proportional hazards regressionTriple-negative breast cancerProportional hazards regressionHigher immunohistochemical expressionTop upstream regulatorsMulti-institutional studyMann-Whitney U testCanonical pathwaysTop canonical pathwaysErbB family membersHER3 levelsPreclinical evidenceClinical outcomesHazards regressionHepatic fibrosisImmunohistochemical biomarkersImmunohistochemical expressionLuminal cytokeratinsMultivariable modelEGFR levelsFibrotic processHormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients
Li X, Yang J, Krishnamurti U, Huo L, Ward K, O'Regan R, Peng L. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients. Clinical Breast Cancer 2017, 17: 356-366. PMID: 28576631, DOI: 10.1016/j.clbc.2017.03.005.Peer-Reviewed Original ResearchConceptsMale breast carcinomaFemale breast carcinomaHormone receptorsMBC patientsWorse OSOverall survivalBreast carcinomaBreast cancerStage IHormone receptor-positive breast cancerEarly-stage hormone receptorReceptor-positive breast cancerNational Cancer Institute's SurveillanceEnd Results (SEER) databaseWorse overall survivalBreast carcinoma casesSimilar survival ratesMBC subtypesWorse survivalClinicopathologic featuresOverall incidenceResults databaseWorse prognosisHER2 statusFBC patientsNew Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
Li X, Oprea-Ilies G, Krishnamurti U. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. Archives Of Pathology & Laboratory Medicine 2017, 141: 490-498. PMID: 28353377, DOI: 10.5858/arpa.2016-0288-sa.Peer-Reviewed Original ResearchConceptsBreast cancerDaily practiceBreast specimensTriple-negative breast cancerDistinct biological subsetsHER2/neu gene amplificationTumor-infiltrating lymphocytesRadioactive seed localizationAppropriate treatment groupsNovel clinical practicesNeu gene amplificationNeoadjuvant treatmentPathologic evaluationHistopathologic parametersTreatment groupsClinical practiceTherapeutic utilityBiological subsetsCancerMolecular classificationBest treatmentPathologyNew guidelinesSeed localizationGene amplificationMulti-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer
Ogden A, Garlapati C, Li X, Turaga R, Oprea-Ilies G, Wright N, Bhattarai S, Mittal K, Wetherilt C, Krishnamurti U, Reid M, Jones M, Gupta M, Osan R, Pattni S, Riaz A, Klimov S, Rao A, Cantuaria G, Rida P, Aneja R. Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Scientific Reports 2017, 7: 42289. PMID: 28218233, PMCID: PMC5316996, DOI: 10.1038/srep42289.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalTNBC cellsOverall survivalPoor prognosisBreast cancerTriple-negative breast cancer patientsTriple-negative breast cancerMultivariable Cox modelMetastasis-free survivalWorse overall survivalBreast cancer patientsMulti-institutional studyAA TNBC patientsAfrican AmericansAfrican American womenTNBC patientsIndependent biomarkerPrognostic valueCancer patientsWorse outcomesCox modelTissue microarrayKIFC1 knockdownTNBCTumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers
Krishnamurti U, Wetherilt C, Yang J, Peng L, Li X. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers. Human Pathology 2017, 64: 7-12. PMID: 28153508, DOI: 10.1016/j.humpath.2017.01.004.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsyBreast NeoplasmsChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalFemaleHumansLogistic ModelsLymphatic MetastasisLymphocytes, Tumor-InfiltratingMastectomyMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPredictive Value of TestsProportional Hazards ModelsReceptors, EstrogenRisk FactorsTime FactorsTreatment OutcomeTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerTumor-infiltrating lymphocytesDisease-free survivalBetter overall survivalLymph node statusOverall survivalBreast cancerNeoadjuvant treatmentLymphovascular invasionEstrogen receptor-positive breast cancerReceptor-positive breast cancerOncotype DX recurrence scoreOncotype DX scorePossible prognostic valueDX recurrence scoreNottingham histologic gradeNeoadjuvant settingTILs correlateNegative associationNode statusPrognostic valueRecurrence scoreHistologic gradePrognostic parametersPathological response
2016
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer
Li X, Wetherilt C, Krishnamurti U, Yang J, Ma Y, Styblo T, Meisel J, Peng L, Siddiqui M, Cohen C, Aneja R. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. American Journal Of Clinical Pathology 2016, 146: 496-502. PMID: 27686176, DOI: 10.1093/ajcp/aqw134.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBetter disease-free survivalDisease-free survivalPD-L1 expressionPD-L1 stainingTumor-infiltrating lymphocytesStromal PD-L1 expressionPD-1 stainingLymphovascular invasionOverall survivalBreast cancerH-scoreTNBC casesTumor sizeCell death protein 1PD-1 expressionLymph node statusDeath protein 1Worse overall survivalKi-67 scoreFull-face sectionsNottingham histologic gradeNeoadjuvant therapyPD-1Node statusBiomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Li X, Krishnamurti U, Bhattarai S, Klimov S, Reid M, O’Regan R, Aneja R. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. American Journal Of Clinical Pathology 2016, 145: 871-878. PMID: 27298399, DOI: 10.1093/ajcp/aqw045.Peer-Reviewed Original ResearchConceptsPathologic complete responseNeoadjuvant chemotherapyEstrogen receptorComplete responseLuminal subtypeProgesterone receptorBreast cancerTriple-negative breast cancer subtypeNottingham grade 3Stromal lymphocytic infiltrationNegative breast cancer subtypeBreast cancer patientsBreast cancer subtypesHigh mitotic countPR negativityHER2 positivityOverall cohortLymphocytic infiltrationTNBC subtypesCancer patientsHER2 statusPathologic parametersKi67 indexNuclear gradeClinical dataA multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.
Bhattarai S, Xia J, Sonmez Wetherilt C, Pattni S, Klimov S, Riaz A, Aleskandarany M, Green A, Rakha E, Ellis I, Cantuaria G, Li X, Krishnamurti U, Osan R, Rida P, Aneja R. A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers. Journal Of Clinical Oncology 2016, 34: 1089-1089. DOI: 10.1200/jco.2016.34.15_suppl.1089.Peer-Reviewed Original Research
2014
HER2 in Breast Cancer
Krishnamurti U, Silverman J. HER2 in Breast Cancer. Advances In Anatomic Pathology 2014, 21: 100-107. PMID: 24508693, DOI: 10.1097/pap.0000000000000015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDrug DesignFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesMolecular Targeted TherapyPrecision MedicinePredictive Value of TestsProtein Kinase InhibitorsReceptor, ErbB-2Signal TransductionTreatment OutcomeUp-RegulationConceptsBreast cancerHER2 receptorTime of diagnosisInvasive breast cancerHER2 receptor overexpressionValuable therapeutic targetHER2 biologyASCO guidelinesHER2 statusHER2 amplificationHER2 testingHER2 oncogeneTherapeutic targetReceptor overexpressionHER2CancerMembrane tyrosine kinaseTumor developmentCell proliferationCurrent standardReceptorsTyrosine kinaseChromosome 17q12RecurrenceTherapyThe Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma
Krishnamurti U, Silverman J. The Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma. Advances In Anatomic Pathology 2014, 19: 13-17. DOI: 10.1097/pcr.0000000000000016.Peer-Reviewed Original ResearchAdverse prognostic factorHER2 amplificationBreast cancerPrognostic factorsHuman epidermal growth factor receptor 2 (HER2) oncoproteinCopy number alterationsInvasive breast cancerInvasive breast carcinomaHER2/CEP17HER2 gene amplificationNumber alterationsHER2 copy numberChromosome 17 polysomyCEP17 duplicationMost patientsHER2 overexpressionBreast carcinomaClinicopathologic significanceHER2 2Chromosome 17PatientsCancerProtein overexpressionCopy numberHER2